Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01838018|
Recruitment Status : Completed
First Posted : April 23, 2013
Last Update Posted : May 28, 2018
|Condition or disease|
|Pantothenate Kinase-associated Neurodegeneration (PKAN)|
|Study Type :||Observational|
|Actual Enrollment :||10 participants|
|Official Title:||Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)|
|Actual Study Start Date :||April 2013|
|Actual Primary Completion Date :||October 2017|
|Actual Study Completion Date :||January 2018|
This group consists of individuals diagnosed with PKAN using a combination of MRI and PANK2 gene sequencing.
This is a control group of healthy volunteers, matched with the PKAN group for age and sex.
- ASL-derived cerebral blood flow(CBF) [ Time Frame: Single MRI ]The unit of analyses will be the subject and the primary comparison will be the globus pallidus CBF between PKAN and healthy controls.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01838018
|United States, Oregon|
|Oregon Health & Science University|
|Portland, Oregon, United States, 97239|
|Principal Investigator:||Susan J Hayflick, MD||Oregon Health and Science University|